Indapta Therapeutics Announces US FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer

Janssen Presents First-ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Trial of KN046, a Novel Bispecific Antibody Targeting PD-L1 and CTLA-4 in Patients With Advanced Solid Tumors

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

IMscin001 Part 2: A Randomised Phase 3, Open-label, Multicentre Study Examining the Pharmacokinetics, Efficacy, Immunogenicity, and Safety of Atezolizumab Subcutaneous versus Intravenous in Previously Treated Locally Advanced or Metastatic NSCLC

Menstrual Suppression in the Myelosuppressed: A Retrospective Cohort Study

Camrelizumab Plus Apatinib and Temozolomide as First-line Treatment in Patients With Advanced Acral Melanoma

Indapta Therapeutics Announces US FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer

header-info

May, 18, 2023

Indapta received FDA clearance to commence the first-in-human, phase 1 clinical trial of combination G-NK cells with monoclonal antibodies in patients with relapsed/refractory multiple myeloma and lymphoma. The study will begin in the second half of 2023 at The University of Texas MD Anderson Cancer Center.

Access the full article to read more here.